Investigating how a specific gene affects breast cancer outcomes in African American women
TRIM37 is a genetic determinant of racial disparity in metastatic TNBC patients
This study is looking at how a specific gene called TRIM37 affects the aggressive type of breast cancer that often impacts African American women, with the hope of finding better treatments that are specially designed for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11055357 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the TRIM37 gene in the aggressive form of triple negative breast cancer (TNBC) that disproportionately affects African American women. The study aims to identify how variations in this gene contribute to higher mortality rates and poorer outcomes in this population. By analyzing tumor samples and genetic data, researchers will explore the relationship between TRIM37 expression and cancer progression, as well as test targeted therapies that inhibit this gene. The ultimate goal is to develop more effective treatment strategies tailored to the genetic profiles of African American women with TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American women diagnosed with metastatic triple negative breast cancer.
Not a fit: Patients of other ethnicities or those with non-metastatic forms of breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to personalized treatment options that improve survival rates for African American women with metastatic TNBC.
How similar studies have performed: Previous research has shown promising results in targeting genetic determinants in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Bhatnagar, Sanchita — University of California at Davis
- Study coordinator: Bhatnagar, Sanchita
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.